Advaxis, Inc. (ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products.
Here is a short term trade Idea :
Buy Between $0.70 to $0.85.
Hold for 4-8 months.
Stop Loss and Risk:
$0.40. Also there is a risk of reverse stock split so keep an eye on that.
Key Catalyst for price increase in next few days:
|ASCO – Genitourinary Cancers Symposium February 12-15, 2020, San Francisco, California|
|Title: “KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab|
on survival in metastatic, castration-resistant prostate cancer patients with or without
prior exposure to docetaxel”
Presenter: Dr. Mark N. Stein, Associate Professor, Division of Hematology/Oncology, Columbia University Medical Center
Abstract: 126, Poster number F6
Date: Thursday, February 13, 2020
Time: 11:30AM – 1:00 PM, 5:30PM – 6:30 PM PT
|IASLC 2020 Targeted Therapies of Lung Cancer Meeting February 19-22, 2020, Santa Monica, California|
|Session: Immunotherapy Combinations|
Title: A Phase 1 Study of ADXS-503 Alone and in Combination with Pembrolizumab in
Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
Presenter: Dr. Jennifer Carlisle, Assistant Professor, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University
Date: Saturday, February 22, 2020
Time: 7:00 am PT
|Immuno-oncology 360° February 26-28, 2020, New York, New York|
|Session: IO Novel Technologies|
Title: “Clinical Updates for Advaxis’ Pipeline of Lm-based Immunotherapies in
Presenter: Andres A. Gutierrez MD PhD – Advaxis’ Chief Medical Officer and Executive Vice President
Date: Thursday, February 27, 2020
Time: 11:00 am ET